MS Scan is a newsletter designed to keep healthcare providers up to date on the latest literature on topics related to the treatment of multiple sclerosis. Providing concise coverage of recent relevant articles, it also includes a guest editor's perspective on matters that arise in the clinical setting when treating your patients with MS. Please visit the MS Scan Editorial Board.

Issue 26 (2010)
Featured in this issue of MS Scan is an article on the unique role that the nurse plays in the treatment of MS. Additionally, a study using the practice of continuous self-improvement and the Plan-Do-Check-Act (PDCA) cycle to increase patient adherence to medication is reviewed. The effect of antihistamines on local injection site reactions (LISRs) is examined, as is long-term palliative care of MS patients.

Issue 25 (2010)
Featured in this issue of MS Scan is a summary of recently published results from trials of MS therapeutics, specifically, those that are taken orally. The latest clinical trial results of the oral MS therapies cladribine and fingolimod are discussed, along with a round-up of research data on several other oral therapies under investigation. A review of the mind-body connection in MS addresses the roles of depression, gender, and cognitive impairment in the MS disease course.

Issue 24 (2009)
Featured in this issue of MS Scan are summaries of recent studies regarding quality of life (QoL) in MS, MS-related fatigue, and clinical trials in primary-progressive MS (PPMS) and clinically isolated syndrome (CIS). One study examines gender differences in health-related QoL in MS. A round-up of 6 clinical trials tracks the latest findings on MS fatigue. A review of recent PPMS publications reveals the frustrating, yet hopeful search for an efficacious treatment for progressive MS. Finally, early disease-modifying therapy (DMT) in CIS is examined in detail, with a review of recent clinical trials.

Issue 23 (2009)
Featured in this issue of MS Scan are summaries of recent studies aiming to improve injection experiences with the self-administered MS therapies. One study addresses the import of injection anxiety as a barrier to long-term adherence with disease-modifying therapies (DMTs). A round-up from the 2009 Consortium of MS Centers (CMSC) meeting describes reports about thinner needles and the role of nurses in DMT education. Finally, 2 “modern-era” MS studies that compare interferon β and glatiramer acetate are reviewed.

Editorial Board